Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis

By afschroeder • March 23, 2026

Kim GHJ, Woodhead FA, Nair D, Bao H, Lazarus HM, Conoscenti CS, Goldin JG. Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis. BMC Pulm Med. 2026 Mar 23. doi: 10.1186/s12890-026-04234-x. Epub ahead of print. PMID: 41866486.

Tags: HRCT, idiopathic pulmonary fibrosis, Inhaled pirfenidone, interstitial lung disease, KBILD, lung function, minimal clinically important difference, Publications, Pulmonary, Critical Care & Sleep Medicine, Quality of Life

Related Posts

Moderators of the Effects of Telehealth Mindfulness-based Interventions for Chronic Pain: A Secondary Responder Analysis of the LAMP Randomized Controlled Trial

Calvert CM, Hagel Campbell EM, Cross LJS, Bangerter A, Bronfort G, Evans R, Meis LA, Haley A, Leininger B, Matthias M, Polusny M, Allen K,[...]

Leveraging scholarship to lead

Moriates C. Leveraging scholarship to lead. J Hosp Med. 2026 Sep 9. doi: 10.1002/jhm.70478. Epub ahead of print. PMID: 42717657.

Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension

Alotaibi M, Tang A, Sun N, Gurholt I, Yuguchi E, Roberts K, Preston I, Warburton R, Yuan JX, Kim NH, Chan SY, Jain M, Cheng[...]